Author:
Need Anna C,Motulsky Arno G,Goldstein David B
Publisher
Springer Science and Business Media LLC
Reference75 articles.
1. Goldstein, D.B., Tate, S.K. & Sisodiya, S.M. Pharmacogenetics goes genomic. Nat. Rev. Genet. 4, 937–947 (2003).
2. Strittmatter, W.J. et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977–1981 (1993).
3. Conley, R.R. & Kelly, D.L. Management of treatment resistance in schizophrenia. Biol. Psychiatry 50, 898–911 (2001).
4. Meltzer, H.Y. & Okayli, G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry 152, 183–190 (1995).
5. Honigfeld, G., Arellano, F., Sethi, J., Bianchini, A. & Schein, J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J. Clin. Psychiatry 59 Suppl., 3–7 (1998).
Cited by
111 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献